NZ579566A - Modified fgf-21 polypeptides and their uses - Google Patents
Modified fgf-21 polypeptides and their usesInfo
- Publication number
- NZ579566A NZ579566A NZ579566A NZ57956608A NZ579566A NZ 579566 A NZ579566 A NZ 579566A NZ 579566 A NZ579566 A NZ 579566A NZ 57956608 A NZ57956608 A NZ 57956608A NZ 579566 A NZ579566 A NZ 579566A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- naturally encoded
- encoded amino
- polypeptides
- acid
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Provided is a modified human FGF-21 polypeptide comprising a non-naturally encoded amino acid, wherein the non-naturally encoded amino acid has a structure attached to the amino terminal which is any substituent other than a side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, pyrrolysine, or selenocysteine, and wherein the non-naturally encoded amino acid is substituted at a position selected from the group consisting of residues 72, 77, 86, 87, 91, 104, 108, 110, 126, 131, and 146.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/057563 WO2008121563A2 (en) | 2007-03-30 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ579566A true NZ579566A (en) | 2013-01-25 |
Family
ID=48570579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Country Status (1)
Country | Link |
---|---|
NZ (2) | NZ602702A (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2748038T3 (en) | 2011-07-01 | 2020-03-12 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for the treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
ES2828505T3 (en) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Compositions and methods for the treatment of metabolic disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
RS60593B1 (en) | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antibodies binding beta klotho domain 2 and methods of use thereof |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
MX2017004488A (en) | 2014-10-23 | 2017-07-17 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof. |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
-
2008
- 2008-03-19 NZ NZ602702A patent/NZ602702A/en unknown
- 2008-03-19 NZ NZ579566A patent/NZ579566A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ602702A (en) | 2014-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ579566A (en) | Modified fgf-21 polypeptides and their uses | |
EP1629840A4 (en) | Amino acid composition and fluid replacement | |
PE20120358A1 (en) | FGF21 MUTANTS AND USES OF THEM | |
HRP20190923T1 (en) | Therapeutic agents for reducing parathyroid hormone levels | |
AR086969A1 (en) | CONJUGATE UNDERSTANDING OXONTOMODULIN AND A FRAGMENT OF IMMUNOGLOBULIN, AND ITS USE | |
PE20120021A1 (en) | MUTANTS FGF21 | |
PE20181299A1 (en) | NOVELTY OXYNTHOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION TO TREAT OBESITY INCLUDING THEM | |
WO2007133642A8 (en) | Sport drink containing amino acids and carbohydrates | |
TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
UA103015C2 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
UA95235C2 (en) | Glucagon-like-peptide-2 (glp-2) analogues | |
RU2011154243A (en) | CELLULAR OPTIONS WITH IMPROVED EXPRESSION, ACTIVITY AND / OR STABILITY AND THEIR APPLICATION | |
NZ600732A (en) | Oxyntomodulin peptide analogue | |
ES2273447T3 (en) | INSECT RESISTANT TRANSGEN PLANTS AND PROCEDURES TO IMPROVE INSECT ACTIVITY. | |
PE20121393A1 (en) | PEPTIDE ANALOGUE OF OXYNTHOMODULIN | |
JP2006525288A5 (en) | ||
CO6220904A2 (en) | NUCLEIC ACIDS CODING MUTANTS OF ACETOHIDROXIACIDO-SYNTHEASE (AHAS) | |
CA3010982A1 (en) | Alpha chain of the high-affinity ige receptor (fceria) | |
EP4219547A3 (en) | Factor ix polypeptide mutant, its uses and a method for its production | |
WO2009009727A3 (en) | Ghrh analogs and therapeutic uses thereof | |
EP1908492A4 (en) | Metabotropic glutamate receptor activator | |
NZ600363A (en) | Modified porcine somatotropin polypeptides and their uses | |
HRP20191965T1 (en) | Stabilized insulin-like growth factor polypeptides | |
JP2014519526A5 (en) | ||
RU2015146739A (en) | COMPLEXES TYPE SUGARIDE CHAIN-POLIPEPTIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2015 BY FB RICE Effective date: 20130612 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2018 BY CPA GLOBAL Effective date: 20140903 Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2021 BY CPA GLOBAL Effective date: 20140906 Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 19 MAR 2028 BY CPA GLOBAL Effective date: 20140908 |